CLSP 1025
Alternative Names: CLSP-1025Latest Information Update: 11 Nov 2024
Price :
$50 *
At a glance
- Originator Clasp Therapeutics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours